News

Number of submitted proposals – HORIZON-INFRA-2024-TECH-01, HORIZON-INFRA-2024-EOSC-01 and HORIZON-INFRA-2024-DEV-01 (call deadline 12 March 2024)

Published on | 1 year ago

Programmes
Research Infrastructures

A total of 163 proposals were submitted to the 2024-01 research infrastructures calls with deadline 12 March 2024.

For the call HORIZON-INFRA-2024-TECH-01 Next generation of scientific instrumentation, tools, methods, and advanced digital solutions for RIs (2024) 69 proposals have been submitted. The breakdown per topic is:

 

For the call HORIZON-INFRA-2024-EOSC-01 Enabling an operational, open and FAIR EOSC ecosystem (2024) 22 proposals have been submitted. The breakdown per topic is:

 

For the call HORIZON-INFRA-2024-DEV-01 Developing, consolidating and optimising the European research infrastructures landscape, maintaining global leadership (2024) 72 proposals have been submitted. The breakdown per topic is:

 

Evaluation results are expected to be communicated in July 2024.

Source: European Commission Funding and tenders portal

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1793 articles available search in articles 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.